Physician profile
James P Clark
NPI 1306838453
$144,033.28
in general payments reported to CMS, 2019-2025
39 companies · $17K in 2025
The $17K reported for 2025 was more than what 91% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $16K · 2021: $20K · 2022: $30K · 2023: $28K · 2024: $17K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Food and Beverage: $12K · Consulting Fee: $1,700 · Travel and Lodging: $1,024 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47,290.00 |
| Food and Beverage | $11,941.61 |
| Consulting Fee | $1,700.00 |
| Travel and Lodging | $1,023.53 |
| Education | $249.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $75,977.06 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $26,109.73 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Optinose US, INC. | $24,387.49 | 2019-2025 | |
| Csl Behring | $5,272.35 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Regeneron Healthcare Solutions, INC. | $2,534.28 | 2019-2025 | Dupixent |
| Incyte Corporation | $1,998.02 | 2022-2025 | Opzelura, Opzelura |
| Novartis Pharmaceuticals Corporation | $1,234.23 | 2019-2025 | |
| Genzyme Corporation | $1,169.81 | 2019-2025 | |
| Genentech USA, INC. | $733.06 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $676.93 | 2020-2024 | Eohilia, Cuvitru, Aralast |
| Biocryst US Sales Co., LLC | $478.59 | 2021-2025 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $390.34 | 2019-2022 | |
| Grifols USA, LLC | $369.76 | 2019-2025 | Xembify |
| Pfizer INC. | $367.94 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.06 | 2019-2023 | Spiriva Respimat |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $242.54 | 2021-2024 | Rinvoq |
| Kaleo, INC. | $236.66 | 2019-2023 | Auvi-Q |
| Cycle Pharmaceuticals INC | $217.70 | 2025 | Sajazir |
| Pharming Healthcare, INC. | $148.98 | 2019-2024 | Ruconest |
| Insmed, INC. | $144.44 | 2025 | Brinsupri, Arikayce |
| Novo Nordisk INC | $125.00 | 2024 | Wegovy |
| Bio Products Laboratory USA, INC. | $122.85 | 2021-2023 | Gammaplex, Coagadex |
| Shire North American Group INC | $105.80 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $93.24 | 2025 | Neffy |
| Blueprint Medicines Corporation | $83.97 | 2021-2023 | Ayvakit |
| Galderma Laboratories, L.P. | $77.23 | 2024-2025 | Nemluvio |
| Amgen INC. | $69.02 | 2022-2025 | Tezspire |
| Leo Pharma INC. | $68.52 | 2023 | Adbry |
| Alk-Abello, INC | $61.45 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Octapharma USA, INC. | $56.94 | 2021 | |
| Sanofi-Aventis U.S. LLC | $56.84 | 2019-2021 | |
| Phadia US INC. | $47.52 | 2019 | |
| Hospira, INC. | $26.83 | 2021-2022 | |
| Ionis Pharmaceuticals, INC. | $24.49 | 2025 | Dawnzera |
| Uswm, LLC | $20.00 | 2021 | |
| Aimmune Therapeutics, INC. | $18.13 | 2021 | |
| Mylan Specialty L.P. | $16.31 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.17 | 2025 | Xhance |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.